Patents by Inventor Robin A. Robinson

Robin A. Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040121465
    Abstract: Codon optimized polynucleotides for optimal expression of recombinant proteins in eukaryotic cells are provided. The codon optimized polynucleotides encode a viral capsid protein that self assembles into a virus-like particle. The virus-like particle is expressed extracellularly and exhibits conformational antigenic epitopes capable of raising neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the gene products of the codon-optimized polynucleotides are also provided.
    Type: Application
    Filed: February 14, 2003
    Publication date: June 24, 2004
    Applicant: Novavax, Inc.
    Inventor: Robin A. Robinson
  • Publication number: 20040063188
    Abstract: Methods for isolation and purification or recombinant gene products are disclosed. In particular, methods for isolation and purification of extracellular and intracellular viral gene products, including virus-like particles, are disclosed herein.
    Type: Application
    Filed: February 14, 2003
    Publication date: April 1, 2004
    Applicant: Novavax, Inc.
    Inventors: Robin A. Robinson, Mark W. Thompson
  • Publication number: 20030228696
    Abstract: An insect cell line capable of growth in serum-free media and secretion of high levels of recombinant proteins, including virus-like particles, upon infection with recombinant baculoviruses, is provided. Methods involving clonal selection processes, serum-weaning and recombinant protein secretion selection are used to create the insect lines of the invention. This cell line supports replication of baculoviruses, serves as host substrate for baculovirus plaque assays, provides a source of insect proteins, acts as a depot for cell transfection to produce recombinant baculoviruses, and express viral recombinant proteins. Extracellular and intracellular viral recombinant proteins and virus-like particles expressed from this cell line are useful as pharmaceutical compositions, vaccines, or diagnostic reagents.
    Type: Application
    Filed: February 14, 2003
    Publication date: December 11, 2003
    Applicant: Novavax, Inc.
    Inventor: Robin A. Robinson
  • Patent number: 6458562
    Abstract: The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: October 1, 2002
    Assignees: The United States of America as represented by the Secretary of Health and Human Services, Novavax, Inc.
    Inventors: Suzanne U. Emerson, Robert H. Purcell, Sergei A. Tsarev, Robin A. Robinson
  • Patent number: 6054567
    Abstract: The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: April 25, 2000
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novavax, Inc.
    Inventors: Suzanne U. Emerson, Robert H. Purcell, Sergei A. Tsarev, Robin A. Robinson